Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients.
Omayma A KishkIvone KimCarmen ChengMukesh SummanMonica A MuñozPublished in: Pediatric nephrology (Berlin, Germany) (2024)
Our case series identified the risk of fibrosing colonopathy in patients taking cysteamine DR and prompted regulatory action by the FDA. As outlined in changes to the U.S. prescribing information for cysteamine DR, healthcare professionals should be aware of the potential risk of fibrosing colonopathy with cysteamine DR, especially as symptoms can be non-specific leading to misdiagnosis or delayed diagnosis. If the diagnosis of fibrosing colonopathy is confirmed, consideration should be given to permanently discontinuing cysteamine DR and switching to cysteamine immediate-release treatment.
Keyphrases
- end stage renal disease
- interstitial lung disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- editorial comment
- peritoneal dialysis
- primary care
- systemic sclerosis
- transcription factor
- emergency department
- rheumatoid arthritis
- patient reported outcomes
- healthcare
- risk assessment
- idiopathic pulmonary fibrosis
- sleep quality
- health information
- combination therapy